Hearts Cracked Open: Trumps’ Shift on Psychedelic Medicine Sparks Hope and Scientific Debate
A new executive order signed by President Donald Trump aims to accelerate FDA reviews and research into psychedelic-assisted therapies, marking a significant shift toward alternative mental health treatments for veterans and trauma survivors. While clinical trials show that compounds like MDMA and psilocybin can dramatically alleviate severe PTSD and depression, the scientific community remains divided.
Researchers caution against letting political momentum outpace rigorous safety evaluations, highlighting the complex, supervised nature of these treatments and the distinct cardiovascular risk associated with substances like ibogaine.
“While drugs like psilocybin and ibogaine — a psychoactive compound derived from a West African shrub that some advocates believe may help treat addiction and traumatic brain injuries — are considered classic psychedelics, MDMA is technically classified as an empathogen.”
